Research ExplorerPublicationsCompositions and Methods of Immunotherapy Targeting Tigit an...

Compositions and Methods of Immunotherapy Targeting Tigit and/or CD112R.

Standard

Compositions and Methods of Immunotherapy Targeting Tigit and/or CD112R. / Riddell, Stanley R; Berger, Susanna Carolina; Srivastava, Shivani.

Patent No.: WO 2019/079777 Al.

Research output: Patent

Harvard

Riddell, SR, Berger, SC & Srivastava, S, Compositions and Methods of Immunotherapy Targeting Tigit and/or CD112R., Patent No. WO 2019/079777 Al.

APA

Riddell, S. R., Berger, S. C., & Srivastava, S. (2018). Compositions and Methods of Immunotherapy Targeting Tigit and/or CD112R. (Patent No. WO 2019/079777 Al).

Vancouver

Riddell SR, Berger SC, Srivastava S. Compositions and Methods of Immunotherapy Targeting Tigit and/or CD112R. WO 2019/079777 Al. 2018.

Bibtex

@misc{2d8db537b42e4c1c84d7a1c81d534f5a,
title = "Compositions and Methods of Immunotherapy Targeting Tigit and/or CD112R.",
abstract = "The present disclosure provides compositions for treating solid tumors, including modified immune cells that specifically target tumor-associated antigens for immunotherapies, wherein expression or activity of T cell immunoreceptor with Ig and ITIM o domains (TIGIT) and/or CD 112R in the modified immune cells is inhibited to improve antitumor functionality of the cells. Alternatively, CD226 is overexpressed in such modified immune cells. Also provided are methods for treating solid tumors, such as tumors formed o by common epithelial cancers.",
author = "Riddell, {Stanley R} and Berger, {Susanna Carolina} and Shivani Srivastava",
year = "2018",
language = "English",
type = "Patent",
note = "WO 2019/079777 Al; A61K 39/00",

}

RIS

TY - PAT

T1 - Compositions and Methods of Immunotherapy Targeting Tigit and/or CD112R.

AU - Riddell, Stanley R

AU - Berger, Susanna Carolina

AU - Srivastava, Shivani

PY - 2018

Y1 - 2018

N2 - The present disclosure provides compositions for treating solid tumors, including modified immune cells that specifically target tumor-associated antigens for immunotherapies, wherein expression or activity of T cell immunoreceptor with Ig and ITIM o domains (TIGIT) and/or CD 112R in the modified immune cells is inhibited to improve antitumor functionality of the cells. Alternatively, CD226 is overexpressed in such modified immune cells. Also provided are methods for treating solid tumors, such as tumors formed o by common epithelial cancers.

AB - The present disclosure provides compositions for treating solid tumors, including modified immune cells that specifically target tumor-associated antigens for immunotherapies, wherein expression or activity of T cell immunoreceptor with Ig and ITIM o domains (TIGIT) and/or CD 112R in the modified immune cells is inhibited to improve antitumor functionality of the cells. Alternatively, CD226 is overexpressed in such modified immune cells. Also provided are methods for treating solid tumors, such as tumors formed o by common epithelial cancers.

M3 - Patent

M1 - WO 2019/079777 Al

Y2 - 2018/10/19

ER -